Diclofenac-Associated Hepatotoxicity Guidelines

Patient Risk Factors and Contraindications

• Patients over 50 years of age are at increased risk for NSAID-induced liver injury, according to the Praxis Medical Insights guidelines 1
• NSAIDs, including diclofenac, are absolutely contraindicated in patients with cirrhosis and ascites due to the high risk of acute renal failure, hyponatremia, and diuretic resistance, as stated by the Praxis Medical Insights guidelines 1, 2
• Patients with advanced liver disease (Child-Pugh B or C) should never receive NSAIDs, as bleeding problems and renal failure become substantially more likely, according to the Praxis Medical Insights guidelines 1, 2

Monitoring and Treatment

• Establish baseline liver function tests (AST, ALT, alkaline phosphatase, total bilirubin) before initiating diclofenac, and monitor transaminases within 4-8 weeks after initiating treatment, then every 3 months during long-term therapy, as recommended by the Praxis Medical Insights guidelines 1
• Discontinue diclofenac immediately if transaminases rise to ≥3× ULN, according to the Praxis Medical Insights guidelines 1
• If hepatic decompensation occurs, the drug cannot be restarted, as stated in the Alimentary Pharmacology and Therapeutics journal 3

Clinical Algorithm

• For patients with fatty liver disease, the FIB-4 score can be used to guide NSAID use: FIB-4 <1.3, exercise caution and prefer acetaminophen; FIB-4 1.3-2.67, strong avoidance of all NSAIDs recommended; FIB-4 >2.67, NSAIDs absolutely contraindicated, as recommended by the Praxis Medical Insights guidelines 1

Diclofenac-Induced Liver Injury

Patient Risk Factors

• Patients with pre-existing chronic liver disease who develop drug-induced liver injury experience significantly higher frequency of adverse outcomes, including mortality, according to the American Association for the Study of Liver Diseases 4

Monitoring and Stopping Criteria

• If ALT ≥8× ULN with or without symptoms, interrupt study drug immediately, repeat tests within 2-5 days, and initiate workup for competing etiologies, as recommended by the European Association for the Study of the Liver 5
• If ALT ≥3× ULN with total bilirubin ≥2× baseline, interrupt drug immediately, as this represents Hy's Law criteria predicting severe outcomes, according to the European Association for the Study of the Liver 5
• If hepatic decompensation occurs, the drug cannot be restarted under any circumstances, as recommended by the European Association for the Study of the Liver 5